Incyte Corporation ($INCY) Stock Forecast: Down 1.4% Today

What is Incyte Corporation?

Incyte Corporation ($INCY) is a biopharmaceutical company specializing in innovative therapies for various diseases, particularly rare conditions.

Why is Incyte Corporation going down?

INCY stock is down 1.4% on Dec 8, 2025 16:10

• Today's downward movement in Incyte Corporation's stock could be linked to profit-taking by investors following a string of positive developments.
• In spite of recent upgrades and promising clinical data shared at a medical conference, the stock may have dipped as investors secured profits.
• The initial surge in stock price due to increased investments from institutional shareholders like American Century Companies Inc. and Invesco Ltd. might have been counterbalanced by subsequent selling pressure.
• The broader market sentiment towards biopharmaceutical firms and the healthcare industry could have also played a role in the stock's decline today.

INCY Price Chart

INCY Technical Analysis

INCY News

Incyte Corporation $INCY Shares Purchased by American Century Companies Inc.

American Century Companies Inc. increased its stake in Incyte Corporation ($INCY) by 20.6% in the second quarter, bringing their total holdings to 78,161 shares valued at $5.32 million. Other institutional investors also modified their positions. Analysts have a consensus "Hold" rating for Incyte, with an average price target of $93.85. The article also provides details on Incyte's financial performance, recent insider transactions, and company profile.

https://www.marketbeat.com/instant-alerts/filing-incyte-corporation-incy-shares-purchased-by-american-century-companies-inc-2025-12-08/

Invesco Ltd. Acquires 232,268 Shares of Incyte Corporation $INCY

Invesco Ltd. increased its stake in Incyte Corporation (NASDAQ:INCY) by 7.3% during the second quarter, acquiring an additional 232,268 shares and bringing its total holdings to 3,401,018 shares valued at $231.6 million. The biopharmaceutical company has shown strong earnings, with a reported $2.26 EPS for the quarter, surpassing analyst estimates, and its stock has performed well, opening at $102.52 with a market cap of $20.13 billion.

https://www.marketbeat.com/instant-alerts/filing-invesco-ltd-acquires-232268-shares-of-incyte-corporation-incy-2025-12-08/

Mizuho upgrades Incyte stock rating to Outperform on promising ASH data

Mizuho upgraded Incyte (NASDAQ:INCY) to Outperform from Neutral, raising its price target to $121.00 from $90.00 following promising clinical data presented at the American Society of Hematology (ASH) annual meeting. The upgrade was driven by Incyte's 989 (mutCALR) therapy for myelofibrosis, which showed strong early dose escalation data, and the potential of its pipeline to offset the upcoming loss of exclusivity for Jakafi. Other recent positive developments for Incyte include strong Q3 performance, a raised guidance, and an exclusive option to acquire Prelude Therapeutics’ JAK2V617F inhibitor program.

https://www.investing.com/news/analyst-ratings/mizuho-upgrades-incyte-stock-rating-to-outperform-on-promising-ash-data-93CH-4395400

Incyte stock price target raised by BofA to $118 on promising blood disorder data

BofA Securities has raised its price target for Incyte (NASDAQ: INCY) to $118 from $114, maintaining a Buy rating. This upgrade follows promising clinical data for Incyte’s INCA033989 monoclonal antibody treatment for myelofibrosis, which demonstrated strong efficacy and a favorable safety profile. The company's financial health, revenue growth, and analyst confidence further support the positive outlook.

https://www.investing.com/news/analyst-ratings/incyte-stock-price-target-raised-by-bofa-to-118-on-promising-blood-disorder-data-93CH-4395451

Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Protagonist Therapeutics and Takeda Pharmaceutical have developed rusfertide, a drug offering a therapeutic intervention for the rare blood cancer polycythemia vera. Longer-term Phase 3 data presented at the American Society of Hematology meeting showed that the drug reduced the need for therapeutic phlebotomies and improved patients' quality of life. The drug aims to replace the archaic practice of regular blood removal by regulating iron absorption to reduce red blood cell production, representing a significant advancement in treating this condition.

https://medcitynews.com/2025/12/protagonist-takeda-rusfertide-polycythemia-vera-rare-blood-disease-ash-tak-ptgx/

Trending Today

Dash ($DASH) Crypto Forecast: Down 6.5% Today

Incyte Corporation Price History

30.06.2025 - INCY Stock was up 5.9%

• INCY stock experienced a strong bullish movement today.
• The bullish trend can be attributed to Incyte reporting better-than-expected Q2 earnings and revenues, driven by strong sales of Jakafi and Opzelura.
• The company's upward revisions in guidance for Jakafi demand and other oncology products have also contributed to the positive market sentiment.
• Investors are optimistic about the company's performance in the upcoming quarters, especially with the success of their key products and new launches driving revenues.

28.09.2025 - INCY Stock was down 5.0%

• The bearish movement in INCY stock today could be attributed to profit-taking by investors ahead of the company's Q3 earnings report.
• Despite expectations of strong performance driven by key products like Jakafi and Opzelura, investors may have been cautious due to uncertainties surrounding new product launches like Niktimvo.
• The anticipation of a potential earnings beat may have already been priced into the stock, leading to a sell-off post-news headlines.
• Market sentiment may have also been influenced by broader industry trends or economic indicators impacting the biopharmaceutical sector.

29.06.2025 - INCY Stock was up 9.1%

• Incyte (INCY) exceeded Q2 earnings and revenue expectations, showcasing a robust performance in the quarter.
• The revenue growth of 16% to $1.22B and EPS of $1.57 compared to a loss of $1.82 YoY contributed to the bullish sentiment.
• Upward revisions in Jakafi guidance to $3-$3.05 billion for 2025, along with positive outlooks on other oncology products, fueled investor optimism.
• The strong performance in Q2, driven by successful products like Jakafi, Opzelura, and new launches, led to increased confidence in Incyte's future prospects, resulting in the bullish market movement.

29.06.2025 - INCY Stock was up 6.0%

• Expectations of a strong Q2 performance with key products like Jakafi, Opzelura, and Niktimvo driving revenues likely contributed to the bullish movement.
• Anticipation of an earnings beat in the upcoming report could have attracted investors to buy INCY stock, leading to the bullish movement.
• Positive sentiment surrounding the company's product portfolio and potential growth prospects might have fueled investor confidence, pushing the stock higher.

26.05.2025 - INCY Stock was up 5.0%

• The FDA approval for the expanded use of Monjuvi in lymphoma is a significant milestone for Incyte, underscoring the company's commitment to developing effective treatments for challenging conditions.
• The approval of Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma creates a new revenue stream for Incyte and strengthens its position in the oncology market.
• The strong bullish movement in INCY stock today is likely influenced by this positive development, as investors react favorably to the company's growth prospects and expanding product portfolio in the competitive biopharmaceutical industry.

04.10.2025 - INCY Stock was up 9.1%

• The bullish movement in Incyte's stock is likely due to positive advancements in their partnership with Prelude Therapeutics for potential disease-modifying treatments and the company's robust financial performance in Q3, surpassing revenue expectations and demonstrating growth potential in the face of patent concerns. These factors, combining positive developments and financial success, probably boosted investor optimism and led to the stock's upward trajectory.

17.09.2025 - INCY Stock was down 5.7%

• The comparison between INCY and ARGX for better value stock might have highlighted weaknesses in INCY's financials or growth prospects, leading to a bearish movement.
• Investors may have reevaluated INCY's position in the market and decided to shift their investments towards other companies with more promising value propositions.
• This assessment could have triggered a sell-off in INCY's stock, driving the bearish movement observed today.
• It is essential for investors to carefully analyze the underlying factors driving such comparisons to make informed decisions about their investment strategies.

08.11.2025 - INCY Stock was down 1.4%

• Today's downward movement in Incyte Corporation's stock could be linked to profit-taking by investors following a string of positive developments.
• In spite of recent upgrades and promising clinical data shared at a medical conference, the stock may have dipped as investors secured profits.
• The initial surge in stock price due to increased investments from institutional shareholders like American Century Companies Inc. and Invesco Ltd. might have been counterbalanced by subsequent selling pressure.
• The broader market sentiment towards biopharmaceutical firms and the healthcare industry could have also played a role in the stock's decline today.

11.02.2025 - INCY Stock was down 2.7%

• Positive phase III study results for Opzelura in treating prurigo nodularis may have heightened investor expectations.
• The significant downward movement in INCY's stock suggests the market may have factored in the positive outcomes already, resulting in a sell-off post-announcement.
• Investors seem to be capitalizing on the news by selling for profit, causing a temporary decline in the stock price despite Opzelura's promising efficacy results.

11.02.2025 - INCY Stock was down 5.7%

• INCY is the stock symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
• ASSESSMENT:
• The bearish movement in INCY stock today could be due to profit-taking by investors after a strong positive run following the news of Opzelura's superior efficacy in prurigo nodularis studies.
• Despite the positive data from the phase III studies and the encouraging efficacy of their partnered FDA-approved drug, investors may have been expecting even better results, leading to a sell-off.
• The market might be reacting to concerns about the sustainability of the positive outcomes reported, leading to a temporary dip in the stock price.

17.02.2025 - INCY Stock was up 5.1%

• Today's surge in Incyte's stock value is a direct result of the successful outcomes from the Phase 3 STOP-HS trials for their latest chronic skin disease medication, Povorcitinib.
• Initial hesitance in the stock price during pre-market trading, attributed to mixed reviews of the trial data, was overshadowed by the drug's effectiveness in patients previously treated with biologics, along with the positive rates of HiSCR50.
• Furthermore, the positive reception towards Incyte's pioneering treatments is reinforced by the promising results of an FDA-approved drug, a collaboration with Eli Lilly, which showed substantial efficacy in young patients grappling with patchy hair loss.
• The continuous progress in Incyte's product pipeline and its commitment to addressing unmet medical needs have instilled confidence in investors regarding the company's potential for future growth, fueling the optimistic upturn in the stock value.

29.09.2025 - INCY Stock was up 7.2%

• Incyte Corporation demonstrated robust growth in third-quarter revenue, exceeding consensus estimates and displaying a 20% year-over-year increase in total revenues.
• The strong performance in Q3 was attributed to higher sales figures of key products like Jakafi, Opzelura, and recent launches, indicating positive revenue prospects for the company.
• Despite concerns regarding a patent expiration in 2028, the company's recent quarter results have bolstered investor confidence, resulting in a bullish market trend for INCY stock today.